My publications – Vibe Gedsø Frøkjær

Stress-Hormone Dynamics and Working Memory in Healthy Women Who Use Oral Contraceptives Versus Non-Users

Front Endocrinol (Lausanne). 2021 Nov 8;12:731994. doi: 10.3389/fendo.2021.731994. eCollection 2021. ABSTRACT BACKGROUND: Women who use oral contraceptives (OCs) may have a higher risk of developing a depression, which is associated with both vulnerability to stress and cognitive dysfunction. OCs disrupt the hypothalamic-pituitary-gonadal (HPG) axis by suppressing endogenous sex steroid production including estradiol. The HPG axis […]?

Stress-Hormone Dynamics and Working Memory in Healthy Women Who Use Oral Contraceptives <em>Versus</em> Non-Users

NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD

J Psychiatr Res. 2021 Jun 18;141:57-65. doi: 10.1016/j.jpsychires.2021.06.021. Online ahead of print. ABSTRACT While several electroencephalogram (EEG)-based biomarkers have been proposed as diagnostic or predictive tools in major depressive disorder (MDD), there is a clear lack of replication studies in this field. Markers that link clinical features such as disturbed wakefulness regulation in MDD with […]?

Brain reactivity during aggressive response in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator

Neuropsychopharmacology. 2021 Apr 29. doi: 10.1038/s41386-021-01010-9. Online ahead of print. ABSTRACT Premenstrual dysphoric disorder (PMDD) is a psychiatric condition characterized by late luteal phase affective, cognitive, and physical impairment. The disorder causes significant suffering in about 5% of women in their reproductive age. Altered sensitivity of cognitive-affective brain circuits to progesterone and its downstream metabolite […]?

Pretreatment qEEG biomarkers for predicting pharmacological treatment outcome in major depressive disorder: Independent validation from the NeuroPharm study

Eur Neuropsychopharmacol. 2021 Apr 25;49:101-112. doi: 10.1016/j.euroneuro.2021.03.024. Online ahead of print. ABSTRACT Several electroencephalogram (EEG) biomarkers for prediction of drug response in major depressive disorder (MDD) have been proposed, but validations in larger independent datasets are missing. In the current study, we investigated the prognostic value of previously suggested EEG biomarkers. We gathered data that […]?

Default Mode Network Functional Connectivity Negatively Associated with Trait Openness to Experience

Soc Cogn Affect Neurosci. 2021 Apr 23:nsab048. doi: 10.1093/scan/nsab048. Online ahead of print. ABSTRACT Evaluating associations between the five-factor personality domains and resting-state functional connectivity networks (e.g., default mode network, DMN) highlights distributed neurobiological systems linked to behaviorally relevant phenotypes. Establishing these associations can highlight a potential underlying role for these neural pathways in related […]?

Genome-wide gene expression changes in postpartum depression point towards an altered immune landscape

Transl Psychiatry. 2021 Mar 4;11(1):155. doi: 10.1038/s41398-021-01270-5. ABSTRACT Maternal postpartum depression (PPD) is a significant public health concern due to the severe negative impact on maternal and child health and well-being. In this study, we aimed to identify genes associated with PPD. To do this, we investigated genome-wide gene expression profiles of pregnant women during […]?

Associations between the cortisol awakening response and patient-evaluated stress and mood instability in patients with bipolar disorder: an exploratory study

Int J Bipolar Disord. 2021 Mar 1;9(1):8. doi: 10.1186/s40345-020-00214-0. ABSTRACT OBJECTIVE: The Cortisol Awakening Response (CAR) measured as the transient increase in cortisol levels following morning awakening appears to be a distinct feature of the HPA axis. Patients with bipolar disorder (BD) experience daily stress, mood instability (MI) and studies have shown disrupted HPA-axis dynamics. […]?

Reward processing in major depressive disorder and prediction of treatment response – Neuropharm study

Eur Neuropsychopharmacol. 2021 Mar;44:23-33. doi: 10.1016/j.euroneuro.2020.12.010. Epub 2021 Jan 15. ABSTRACT Major depressive disorder (MDD) is a prevalent brain disorder for which anhedonia is a core symptom, indicating aberrations in the neural processing of reward. The striatum, medial prefrontal cortex (mPFC) and anterior insula (AI) are core reward processing regions. Here we used a reward-related, […]?

Reward processing in major depressive disorder and prediction of treatment response – Neuropharm study.

Related Articles Reward processing in major depressive disorder and prediction of treatment response – Neuropharm study. Eur Neuropsychopharmacol. 2021 Jan 14;: Authors: Brandt IM, Köhler-Forsberg K, Ganz M, Ozenne B, Jorgensen MB, Poulsen A, Knudsen GM, Frokjaer VG, Fisher PM Abstract Major depressive disorder (MDD) is a prevalent brain disorder for which anhedonia is a […]?

Archive